Skip to main content

Sage Licenses CRISPR-Cas9 Technology from Broad Institute

NEW YORK (GenomeWeb) – Sage Labs today announced it has licensed CRISPR-Cas9 genome editing technology from the Broad Institute.

The license provides Sage the ability to use the technology — for which Broad recently was awarded the first US patent covering the CRISPR-Cas9 technology — to engineer cell and animal models for its clients. Sage will also be able to distribute validated CRISPR reagents, it said. The St. Louis-based company previously licensed CRISPR-Cas9 technology from Caribou Biosciences.

Financial and other terms of the deal were not disclosed.

Sage provides gene editing tools, research models, and support services. While the Broad received the first CRISPR-Cas9 patent, the IP landscape surrounding the technology is becoming increasingly murky, and in a statement Sage CEO David Smoller said that it is crucial that the firm's clients "receive the freedom to operate with their research models, and we're committed to obtaining the necessary licenses."

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.